Navigation Links
Astellas Promotes Doug Geiger to Vice President, Head of New Therapeutic Areas in Marketing Strategy
Date:10/27/2015

NORTHBROOK, Ill., Oct. 27, 2015 /PRNewswire/ -- Astellas recently announced that Doug Geiger has been promoted to the position of vice president, head of New Therapeutic Areas in Marketing Strategy. Geiger will be responsible for delivering global strategic commercial leadership on key initiatives within Astellas' emerging therapeutic areas. He will report to Yukio Matsui, senior vice president and head of Marketing Strategy.

"Doug has been a pivotal strategic commercial leader since joining Astellas in 2008," said Matsui. "He will play an instrumental role as we establish a presence in new therapeutic focus areas such as pain, central nervous system, nephrology and inflammation."

Geiger brings 23 years of experience in the pharmaceutical industry. He joined Astellas in 2008 as director of New Product Planning in the U.S., and helped establish the oncology business unit. Since 2012, Geiger has served as senior director and head of the New Product Planning in the U.S., where he played a vital role in optimizing the commercial potential of Astellas' pipeline.

Prior to Astellas, Geiger held several commercial leadership positions at Abbott Laboratories and TAP Pharmaceuticals in marketing, commercial strategy and global commercial development. 

Geiger earned his Bachelor of Science in finance from the University of Illinois, holds a Master of Science in accounting from DePaul University Kellstadt Graduate School of Business and a Masters in Business Administration from Northwestern University Kellogg School of Management.  

About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. For more information on Astellas, please visit our website at www.astellas.us, follow us on Twitter at www.twitter.com/AstellasUS or like our Facebook page at www.facebook.com/AstellasUS.

Photo - http://photos.prnewswire.com/prnh/20151027/281191
Logo - http://photos.prnewswire.com/prnh/20140416/84970

 


'/>"/>
SOURCE Astellas
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain
2. Astellas European Foundation gewährt Zuschüsse zur Untersuchung neuartiger molekularer Bildgebungstechniken für Patienten mit Prostatakrebs
3. Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections
4. Julie Monzo Joins Astellas Corporate Affairs
5. Astellas And Medivation Announce Enrollment Of The First Patients In Advanced Prostate Cancer Outcomes Registry
6. Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award
7. Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML)
8. Astellas Pharma EMEA Celebrates Its 10th Anniversary
9. Astellas honors 10 years of patient care and community involvement with Changing Tomorrow Day service activities
10. Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting
11. Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 19, 2020 , ... The Team Type 1 Foundation, a nonprofit organization ... affected by diabetes, announced a partnership with VeloCity, a fundraising ride benefiting Grady Hospital, ... event takes place on May 2nd and begins on the Mercedes-Benz Stadium field and ...
(Date:2/19/2020)... ... ... The swine flu (H1N1) was the virus that spread from animals to humans ... Although the U.S. has eradicated this disease after its first and only occurrence in ... a risk from trading partners. , In a new article released in the ...
(Date:2/15/2020)... ... February 14, 2020 , ... February is ... the organisms that cause inflammatory gum disease (e.g., periodontitis) and systemic inflammatory disease ... offers new tools in the fight against common dental problems such as gum ...
Breaking Medicine Technology:
(Date:2/21/2020)... , ... February 21, 2020 , ... ... host the 2021 World Cancer Leaders’ Summit in Boston, MA, in October 2021. ... together key decision makers including prime ministers, ministers of health, city and industry ...
(Date:2/20/2020)... ... February 20, 2020 , ... TMQuotes , a revolutionary ... generation API integration functionality which enables agents to take more involved ownership over ... was the first white label software-as-a-service (SaaS) to give insurance agents and brokers ...
(Date:2/19/2020)... BOSTON (PRWEB) , ... February 19, 2020 , ... ... , MedTech Start Up Founders Encouraged to Apply to Participate in 2020 Cohort ... the MedTech IGNITE program is now accepting applications from startup founders ...
(Date:2/19/2020)... ... February 19, 2020 , ... SafiraMD ... CoolEvent for FDA-cleared CoolSculpting®, the world’s most popular non-invasive fat reduction treatment. Their ... in the Halcyon Village Center in Alpharetta, Georgia. The CoolEvent will feature live ...
(Date:2/15/2020)... ... , ... It all started back in 2010, when Jennifer Martinez (Founder) was ... she was on to something special. The Heartsters have now become a circle ... a health condition or illness, a disability or just having a bad day. ...
Breaking Medicine News(10 mins):